brivaracetam / Generic mfg. - LARVOL DELTA

Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real-world clinical practice. (PubMed, Epileptic Disord) - "This study highlights the real-world effectiveness and safety of cenobamate, either as monotherapy (after conversion from polytherapy) or in dual therapy, in patients with drug-resistant epilepsy. Cenobamate allows for a significant treatment simplification, resulting in fewer treatment-related adverse events without compromising seizure reduction."

Journal • Monotherapy • Real-world evidence • CNS Disorders • Epilepsy • Fatigue

Brivaracetam for status epilepticus: a systematic review. (PubMed, J Neurol) - "BRV may be an effective treatment for SE, RSE, and SRSE, demonstrating efficacy across various seizure semiologies and etiologies, although there are substantial limitations within the available literature."

Journal • Review • CNS Disorders • Epilepsy • Psychiatry • Vascular Neurology

Seizure Clusters: Current Concepts in Definition and Treatment. (PubMed, J Clin Med) - "Consequently, the off-label use of oral benzodiazepines, including clobazam, clonazepam, and lorazepam, remains common when oral therapy is feasible, despite limited evidence. These include prompt intravenous benzodiazepine administration, followed by the intravenous loading of antiseizure medications such as brivaracetam or lacosamide in cases of seizure recurrence. In ED settings, "empirical" definitions of SCs (i.e., more than three seizures within 24 h) may facilitate timely intervention."

Journal • Review • CNS Disorders • Epilepsy

Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift? (PubMed, Neurol Ther) - "In this real-world study, early third-line CNB exhibits potentially favorable effectiveness compared with other commonly used third-line ASMs, and tolerability remained acceptable. These findings support the need for larger prospective studies to better define optimal treatment sequencing in focal-onset DRE."

Journal • CNS Disorders • Epilepsy

Reassessing the adverse event profiles of levetiracetam and brivaracetam: a systematic review and meta-analysis. (PubMed, J Neurol) - "LEV and BRV show favorable safety profiles that appear comparable based on meta-analytic findings, despite higher rates of some psychiatric AEs with LEV on a descriptive level. Both remain safe treatment options, though larger head-to-head trials are needed to provide definitive comparative evidence."

Adverse events • Clinical • Journal • Retrospective data • Review • CNS Disorders • Epilepsy • Fatigue • Pain • Psychiatry

Mortality Risk After Initiation of Cenobamate or Other Antiseizure Medications (AAN 2026) - "Objective: To retrospectively examine all-cause mortality in patients after initiating cenobamate vs mortality in patients treated with selected antiseizure medications (ASMs) that have similar patterns of use in medication-resistant epilepsy.Background: A previous post-hoc analysis of survival in a clinical trial cohort showed that the all-cause standardized mortality ratio (SMR) for cenobamate-treated patients was 1.32 (95% CI: 0.84-2.0), which was not significantly different from the general population.Design/ De-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated therapeutic doses of cenobamate or another selected ASM (brivaracetam, clobazam, lacosamide, eslicarbazepine, or perampanel) between 1/1/2020-12/5/2024. Patients treated with cenobamate at therapeutic doses had lower mortality rates than patients treated with selected comparable ASM."

CNS Disorders • Epilepsy

Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate (AAN 2026) - "Objective: To evaluate the comparative effect of initiating cenobamate vs selected antiseizure medications (ASMs, brivaracetam, clobazam, eslicarbazepine, lacosamide, or perampanel) on epilepsy-related and all-cause inpatient (IP) and emergency room (ER) utilization rates.Background: Cenobamate is an ASM approved for adults in the US that has demonstrated efficacy across focal seizure subtypes.Design/ A retrospective observational study using de-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated cenobamate or another selected ASM between 1/1/202012/52024. Initiating cenobamate was associated with a significant reduction in both epilepsy-related and all-cause IP admissions and ER visits compared to propensity-matched patients who similarly could have initiated cenobamate but instead initiated other ASMs."

HEOR • CNS Disorders • Epilepsy

Refractory Autoimmune Encephalitis with Focal Status Epilepticus in a Patient with KLHL11 Antibody Syndrome (AAN 2026) - " The patient was found to have electroclinical seizures with focal status epilepticus despite extensive anti-seizure medication (ASM) therapy, including brivaracetam, lacosamide, valproic acid, phenobarbital, cenobamate, perampanel, and clobazam. This case illustrates the recurrent and refractory nature of KLHL11 antibody-associated autoimmune encephalitis, particularly when complicated by drug-resistant epilepsy. Early recognition of recurrence and escalation of immunotherapy, including rituximab, may be necessary in managing such cases. Comprehensive neurologic, immunologic, and oncologic evaluations are essential to guide ongoing therapy and improve clinical outcomes."

Clinical • CNS Disorders • Epilepsy • Germ Cell Tumors • Immunology

Depressive Symptom Changes Following Antiseizure Medication (ASM) Use – A Quantitative Analysis of Clinical Studies (AAN 2026) - "Most anti-seizure medications were correlated with symptoms improvement, with the greatest effects observed for Perampanel (d = –0.77), Brivaracetam (d = –0.55), Lacosamide (d = –0.46), and Eslicarbazepine Acetate (d = –0.41). Decreases in depressive symptoms appear to be an underrecognized yet clinically meaningful secondary effect of antiseizure medications. These findings highlight specific medications that may provide the greatest benefit in co-morbid neuropsychiatric symptoms and underscore an importance of integrating psychiatric outcomes into epilepsy treatment decisions."

Clinical • CNS Disorders • Depression • Epilepsy

Horner Syndrome Following Vagal Nerve Stimulator Implantation: A Rare Complication (AAN 2026) - "We report the case of a 16-year-old female with medically refractory epilepsy who developed clinical features of left-sided Horner syndrome immediately following VNS implantation.Design/ A 16-year-old female with drug-resistant epilepsy and a history of developmental delay secondary to childhood lead poisoning underwent VNS implantation after failing multiple anti-seizure medications, including levetiracetam, brivaracetam, oxcarbazepine, and perampanel. Horner syndrome is a rare but important complication of VNS implantation. With very few cases documented in the literature, it remains uncommon, and clinicians should maintain a high index of suspicion when characteristic signs appear postoperatively. The condition is likely caused by unintentional traction or injury to the sympathetic pathway during surgical manipulation near the carotid sheath."

CNS Disorders • Developmental Disorders • Epilepsy • Gastrointestinal Disorder • Infectious Disease • Ophthalmology • Otorhinolaryngology • Pulmonary Disease

EXPAND: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - P3 | N=153 | Active, not recruiting | Sponsor: UCB Biopharma SRL | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Absence Seizure Disorder • CNS Disorders • Epilepsy

Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy. (PubMed, Brain Res) - "BVM loaded MSN treatment reduced to 13.25 ± 1.11 episodes (18.46% antiepileptic effect), while mannose-conjugated BVM-loaded MSN group further decreased to 12.5 ± 1.32 episodes (23.07% antiepileptic activity). These results suggest that surface functionalized MSN are promising for sustained drug delivery for improved seizure control."

Journal • CNS Disorders • Epilepsy

Brivaracetam induced Acute Kidney Injury (NKF-SCM 2026) - "INTRODUCTION Brivaracetam (BRV) is antiepileptic with a higher affinity for the target, synaptic vesicle protein 2A than Levetiracetam...METHODS/CASE SUMMARY A 22-year-old male with epilepsy diagnosed one year prior, adherent to lacosamide, presented with a breakthrough generalized tonic–clonic seizure...He was subsequently transitioned to oxcarbazepine long-term...CONCLUSION This case raises concern for a direct nephrotoxic effect of BRV, independent of RML or hypersensitivity reaction. Further pharmacovigilance, case accumulation, and mechanistic studies are needed to characterize the renal safety of BRV and identify at-risk patients."

Acute Kidney Injury • CNS Disorders • Epilepsy • Immunology • Nephrology • Renal Disease

SCN9A mutations may contribute to medically refractory epilepsy (AAN 2026) - "His seizures were refractory to brivaracetam, lacosamide, zonisamide, oxcarbazepine. He is currently on clobazam, felbamate and valproic acid, with seizures occurring every other week...He is currently on zonisamide, levetiracetam, rufinamide, cannabidiol, and clobazam and continues to have seizures every few days... These cases demonstrate SCN9A gene mutations in patients with refractory epilepsy, suggesting a possible link. These specific gene mutations have not been well characterized in literature; thus, these cases may provide insight into mutations that may be pathogenic. Further research is necessary to determine exactly what role these variants play in epilepsy."

CNS Disorders • Epilepsy • NAV1 • SCN8A

Novel GTPBP2 Mutation-associated Jaberi Elahi Syndrome – A Rare Cause of Syndromic Epilepsy (AAN 2026) - "This case describes a novel gene variant associated with JABELS, and adds to the limited fund of knowledge on the clinical presentation and genetic causes of this extremely rare disorder."

CNS Disorders • Developmental Disorders • Dystonia • Epilepsy • Movement Disorders • Rare Diseases

The Cognitive Outcomes of Switching from Levetiracetam to Brivaracetam: A Retrospective Cohort Study. (AAN 2026) - "Switching from LEV to BRV showed improvement in patient cognitive function, with enhancement in recall, attention, and speed. These results are promising but warrant further investigations with a larger sample size to confirm our results."

Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy

NUS1-Related Novel Start Codon Variant: Expanding the Progressive Myoclonus Ataxia Spectrum (AAN 2026) - "This is the oldest reported patient with a novel start codon variant NUS1-related disorder with Epilepsy-myoclonus-ataxia syndrome without definite cortical myoclonus. She has never had a generalized tonic clonic seizure, but her frequent EEG surface negative myoclonus is responsive to brivaracetam. This patient highlights the phenotypic variability of this disorder."

Ataxia • CNS Disorders • Developmental Disorders • Epilepsy • Movement Disorders • Ophthalmology • Strabismus

Thoracocervicofacial Petechial Rash Following Breakthrough Seizures in a Case of Parietal Encephalomalacia (AAN 2026) - "Few well-documented cases exist in the literature.Design/ N/A A 48-year-old man with a history of traumatic brain injury, right parietal encephalomalacia, and chronic seizure disorder on brivaracetam presented after two witnessed generalized tonic–clonic seizures, one occurring during transport... This case adds to limited literature on postictal petechial eruptions. The distribution, benign course, and normal hematologic workup support a mechanical etiology from transient venous hypertension rather than vasculitic or hematologic disease. Recognizing this pattern can prevent unnecessary testing and may serve as a clinical clue to recent convulsive activity, particularly in unwitnessed seizures or postictal states."

Clinical • Cardiovascular • CNS Disorders • Epilepsy • Hematological Disorders • Hypertension • Thrombocytopenia • Vascular Neurology • Vasculitis

Intra-nasal Seletracetam for Reading Epilepsy: A First in Human Proof-of-concept Case Study (AAN 2026) - "Seletracetam (SEL), a levetiracetam analogue ~100-fold and ~10-fold more potent than levetiracetam and brivaracetam, respectively, showed favorable efficacy and safety to Phase 2 at UCB Pharma. In this compassionate-use case, 60 mg intranasal SEL fully prevented reflex seizures. Bitter taste after first, not second, dose suggests partial swallowing, explaining residual seizures and reduced spike frequency. Data support SEL's potential as the first non-benzodiazepine acute seizure treatment."

Case study • Clinical • First-in-human • P1 data • CNS Disorders • Depression • Epilepsy

A Father and Daughter Presentation of Autosomal Dominant Sleep-related Hypermotor Epilepsy via a DEP Domain Containing Protein 5 Deletion in Exon 28 (AAN 2026) - "Currently, seizures are well-controlled in the daughter and father with lacosamide and lacosamide plus brivaracetam, respectively. This case report highlights the importance of clinical presentation and early pattern recognition of seizure type as well as the role of genetic testing and video EEG monitoring in patients with clinical features of ADSHE."

CNS Disorders • Epilepsy • Vascular Neurology • DEPDC5

A Case of Autoimmune Limbic Encephalitis, Myasthenia Gravis, and Malignant Thymoma (AAN 2026) - "Levetiracetam failed to control the seizures, and was later switched to brivaracetam and phenytoin. Due to concern of autoimmune encephalitis, patient was started on high-dose steroids followed by cyclophosphamide... This case highlights the rare coexistence of anti-GAD65 limbic encephalitis and MG in the same patient, probably converging together by a malignant thymoma. Anti-GAD65 LE has been associated with seizures and behavioral changes; rarely linked to malignant tumors (4-6%), most commonly thymoma. Only one other cases of anti-GAD encephalitis associated to MG have been reported in the literature."

Clinical • CNS Disorders • Epilepsy • Immunology • Infectious Disease • Myasthenia Gravis • Solid Tumor • Thymoma • Thymus Cancer

Nonconvulsive Status Epilepticus in MELAS Syndrome Without Stroke-Like Lesions: A Case Report (AAN 2026) - "Continuous EEG showed 2–3 Hz rhythmic spike– and polyspike–wave discharges in the right temporo-parieto-occipital region with anterior propagation, lasting 12–15 seconds, resolving after intravenous midazolam...Antiseizure therapy was optimized with brivaracetam and clobazam, and metabolic therapy with L-arginine and citrulline was reinstated.The patient achieved full clinical and electrographic recovery without new neurological deficits... This case broadens the clinical spectrum of mitochondrial epilepsy, showing that NCSE may occur in MELAS without structural lesions. These findings support metabolic dysfunction as a direct mechanism of epileptogenesis. Sustained nitric oxide precursor therapy and continuous EEG monitoring are essential to prevent recurrence and irreversible neuronal injury."

Case report • Clinical • Cardiovascular • CNS Disorders • Epilepsy • Metabolic Disorders • MTHFR

Adult Lennox Gastaut Syndrome: Clinic Characteristics and Therapeutic Patterns (AAN 2026) - "The most commonly used ASM were Levetiracetam(55.5%), Cannabidiol (40.7%), Lacosamide (33.3%), Lamotrigine (29.6%), and Brivaracetam (29.6%). Adult LGS can remain in refractory despite medical and surgical intervention. Medications used in our cohort differed from Tier 1 pediatric agents. In addition, findings suggest a possible trend in which patients with lower seizure frequency were more likely to exhibit agitation, without reaching statistical significance."

Clinical • CNS Disorders • Epilepsy

Model-Based Steady State Pharmacokinetic Predictions Using High Throughput Cassette Infusion Approach in Mice. (PubMed, Xenobiotica) - "This study assessed the pharmacokinetics (PK) of Fulvestrant, Imipramine, and Brivaracetam using cassette dosing. All compounds reached steady-state within 24-36 hours, and clearance/exposure rankings were consistent across models and experiments. This integrated approach combining SC PK profiling, modeling, and cassette infusion enabled model-informed dose prediction and qualitative validation, which can support early PK evaluation and formulation development in drug discovery."

Journal • PK/PD data • Preclinical

Lupin announced on February 24, 2026, that it received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution (10 mg/mL). (InvestyWise) - "The company immediately initiated the launch in the United States. This product is bioequivalent to UCB, Inc.’s Briviact Oral Solution and treats partial-onset seizures in patients aged 1 month and older. The original product had estimated annual sales of USD 135 million in the U.S."

ANDA • Generic launch • Sales • Epilepsy